Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Current Deferred Revenue: 2019-2022

Historic Current Deferred Revenue for Lyell Immunopharma (LYEL) over the last 2 years, with Sep 2022 value amounting to $11.2 million.

  • Lyell Immunopharma's Current Deferred Revenue rose 100.52% to $11.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $11.2 million, marking a year-over-year increase of 100.52%. This contributed to the annual value of $5.0 million for FY2021, which is 18.16% down from last year.
  • According to the latest figures from Q3 2022, Lyell Immunopharma's Current Deferred Revenue is $11.2 million, which was down 27.45% from $15.4 million recorded in Q2 2022.
  • In the past 5 years, Lyell Immunopharma's Current Deferred Revenue ranged from a high of $45.0 million in Q4 2019 and a low of $5.0 million during Q4 2021.
  • Over the past 3 years, Lyell Immunopharma's median Current Deferred Revenue value was $6.2 million (recorded in 2022), while the average stood at $8.2 million.
  • As far as peak fluctuations go, Lyell Immunopharma's Current Deferred Revenue plummeted by 86.46% in 2020, and later surged by 100.52% in 2022.
  • Lyell Immunopharma's Current Deferred Revenue (Quarterly) stood at $45.0 million in 2019, then plummeted by 86.46% to $6.1 million in 2020, then fell by 18.16% to $5.0 million in 2021, then soared by 100.52% to $11.2 million in 2022.
  • Its last three reported values are $11.2 million in Q3 2022, $15.4 million for Q2 2022, and $6.2 million during Q1 2022.